Clinical Trial Update: Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing the new inhaler FlutiForm HFA MDI 100/10 µg against standard fluticasone/formoterol in asthma patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FlutiForm HFA MDI 100/10 µg (fluticasone propionate/formoterol)
• Fluticasone propionate/formoterol (fluticasone propionate/formoterol)

Snippet

Sponsor: SkyePharma AG | Conditions: Asthma | Phase 3 | Status: COMPLETED